Literature DB >> 21181186

Rhabdomyolysis/myoglobinemia and NSAID during 48 h ultra-endurance exercise (adventure racing).

Emma Wichardt1, C Mikael Mattsson, Björn Ekblom, Karin Henriksson-Larsén.   

Abstract

Our purpose is to determine whether rhabdomyolysis with myoglobinemia exists during a 48+ h adventure race and if there is a correlation with NSAID use, race time and perceived pain or exertion. Blood samples for analyses of myoglobin (Mb) were collected, and perception of exertion and pain was registered on the Borg-RPE and CR scales, from 20 subjects (3 female, 17 male) Pre-, Mid- and Post-race. Subjects were asked about NSAID use at each sampling and within 12 h pre-race. The result observed was a significant rise in Mb throughout the race, with the NSAID group (n = 6) having significantly lower Mb-Post than the no-NSAID group (n = 14). High Mb-Pre and Post correlated to shorter race time and high Mb-Pre to lower Pain-post. Race time also correlated to NSAID use, with the NSAID group having significantly longer race time than the no-NSAID group. Rhabdomyolysis with myoglobinemia, which might be reduced with NSAID use, exists during a 48+ h adventure race. Indications that high Mb-levels correlate with shorter race time and less pain, and the reasons for the NSAID groups longer race time, warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181186     DOI: 10.1007/s00421-010-1774-2

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  25 in total

1.  Ample use of physician-prescribed medications in Finnish elite athletes.

Authors:  A Alaranta; H Alaranta; M Heliövaara; M Airaksinen; I Helenius
Journal:  Int J Sports Med       Date:  2006-02-14       Impact factor: 3.118

2.  Use of permitted drugs in Italian professional soccer players.

Authors:  Emanuela Taioli
Journal:  Br J Sports Med       Date:  2007-02-22       Impact factor: 13.800

3.  Intensity and physiological strain of competitive ultra-endurance exercise in humans.

Authors:  Samuel J E Lucas; Nat Anglem; Warren S Roberts; J Greg Anson; Craig D Palmer; Robert J Walker; Christian J Cook; James D Cotter
Journal:  J Sports Sci       Date:  2008-03       Impact factor: 3.337

4.  Exercise-associated hyponatremia, renal function, and nonsteroidal antiinflammatory drug use in an ultraendurance mountain run.

Authors:  A J Page; S A Reid; D B Speedy; G P Mulligan; J Thompson
Journal:  Clin J Sport Med       Date:  2007-01       Impact factor: 3.638

5.  Effects of a non-steroidal anti-inflammatory drug on delayed onset muscle soreness and indices of damage.

Authors:  A E Donnelly; K McCormick; R J Maughan; P H Whiting; P M Clarkson
Journal:  Br J Sports Med       Date:  1988-03       Impact factor: 13.800

6.  Event medicine: injury and illness during an expedition-length adventure race.

Authors:  David A Townes; Timothy S Talbot; Ian S Wedmore; Robert Billingsly
Journal:  J Emerg Med       Date:  2004-08       Impact factor: 1.484

7.  Mood, illness and injury responses and recovery with adventure racing.

Authors:  Nat Anglem; Samuel J E Lucas; Elaine A Rose; James D Cotter
Journal:  Wilderness Environ Med       Date:  2008       Impact factor: 1.518

8.  A randomized controlled trial of the effect of naproxen on delayed onset muscle soreness and muscle strength.

Authors:  J M Lecomte; V J Lacroix; D L Montgomery
Journal:  Clin J Sport Med       Date:  1998-04       Impact factor: 3.638

9.  Pre-race health status and medical events during the 2005 World Adventure Racing Championships.

Authors:  Richard J Newsham-West; Joanne Marley; Anthony G Schneiders; Andrew Gray
Journal:  J Sci Med Sport       Date:  2008-10-01       Impact factor: 4.319

10.  [Changes in several plasma and urinary components in marathon runners].

Authors:  P Boudou; J Fiet; C Laureaux; M C Patricot; C Y Guezennec; M J Foglietti; J M Villette; F Friemel; J C Haag
Journal:  Ann Biol Clin (Paris)       Date:  1987       Impact factor: 0.459

View more
  3 in total

1.  Multidisciplinary Analysis of Differences Between Finisher and Non-finisher Ultra-Endurance Mountain Athletes.

Authors:  Pedro Belinchón-deMiguel; José Francisco Tornero-Aguilera; Athanasios A Dalamitros; Pantelis T Nikolaidis; Thomas Rosemann; Beat Knechtle; Vicente Javier Clemente-Suárez
Journal:  Front Physiol       Date:  2019-12-10       Impact factor: 4.566

Review 2.  Moving in extreme environments: extreme loading; carriage versus distance.

Authors:  Samuel J E Lucas; Jørn W Helge; Uwe H W Schütz; Ralph F Goldman; James D Cotter
Journal:  Extrem Physiol Med       Date:  2016-04-22

3.  Greater muscle damage in athletes with ACTN3 R577X (RS1815739) gene polymorphism after an ultra-endurance race: a pilot study.

Authors:  T Belli; A H Crisp; R Verlengia
Journal:  Biol Sport       Date:  2017-01-01       Impact factor: 2.806

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.